Lisata Therapeutics Inc (LSTA) Stock Price, Quote & News

Company Profile

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with a range of anti-cancer regimen...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 842 0100

Website: www.lisata.com

Address:

110 Allen Road, 2nd Floor, Basking Ridge, United States

emile_ Feb. 23 at 6:17 PM

$LSTA why is Lisata Therapeutics falling?

0 · Reply

TwongStocks Feb. 20 at 2:19 PM

$LSTA They have 1 week before the deadline to sign a definitive purchase agreement with Kuva. If the purchase agreement is not signed by Feb 27, the term sheet will be terminated unless both Kuva and LSTA agree to extend the deadline. Hopefully, they'll get the purchase agreement finalized next week so they can start the tender process. Will be interesting to see whether the final purchase agreement will have the same terms as the term sheet, $4 upfront with two $1 CVRs. LSTA already terminated the agreement with Qilu, so we know that one of the CVRs will be reached. I'm hoping Kuva might be willing to give $5 upfront with a single $1 CVR in light of the termination of the Qilu agreement.

0 · Reply

BillionerOfKing Feb. 18 at 1:30 PM

$LSTA Current Stock Price: $4.56

0 · Reply

OfficialStocktwitsUser Feb. 17 at 4:00 PM

$LSTA RSI: 48.15, MACD: 0.4935 Vol: 0.56, MA20: 4.36, MA50: 2.96 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

InstitutionalAllocator Feb. 17 at 12:31 PM

$LSTA Pre-revenue biotech; early-stage oncology pipeline.

0 · Reply

FlowMap Feb. 9 at 2:25 PM

$LSTA Biotech or lending platform; business model is unclear from ticker.

0 · Reply

dinnerwithme Feb. 9 at 12:35 PM

$BCAB $LSTA bullish

0 · Reply

biovaluable Feb. 8 at 11:36 PM

$BCAB remember, oil money from AIRC. They'll be looking for a successful IPO of GATC using BioAtla assets. $LSTA, which was GATC's only counterpart except BioAtla, will be acquired by a third party (GURU?) through a recent tender offer. So, the only alternative left for GATC, which is aimed at developing new AI drugs, is BioAtla. Jay's company, which has a market capitalization ($12M) and a 50% stake in in Inversagen AI, which is cheaper than a $40M investment. All condition is that inversagen AI will receive $40M of the investment will be sufficient to buy the company. It could be announced today.

0 · Reply

Squanchass Feb. 6 at 4:11 PM

$LSTA Give me my CVR's!

0 · Reply

biovaluable Feb. 5 at 3:22 PM

$LSTA 6

1 · Reply

Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

Jan 21, 2026, 7:00 AM EST - 4 weeks ago

Lisata Therapeutics Enters Into Term Sheet to be Acquired by Kuva Labs for $4.00 Per Share in an All-Cash Tender Offer

Nov 6, 2025, 7:46 PM EST - 3 months ago

Lisata Therapeutics, Inc. (LSTA) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 3 months ago

Lisata Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 8:00 AM EST - 3 months ago

Lisata Therapeutics Wins 2025 BioTech Breakthrough Award for ‘Overall BioPharma Solution of the Year'

Nov 4, 2025, 4:00 PM EST - 3 months ago

Lisata Therapeutics Highlights Positive Preclinical Data of Certepetide as Part of Antibody-Drug Conjugate Combinations as Reported by Licensing Partner Catalent

Oct 30, 2025, 8:00 AM EDT - 4 months ago

Lisata Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update on Thursday, November 6, 2025

Oct 13, 2025, 8:00 AM EDT - 4 months ago

Lisata Therapeutics to Present at LD Micro Main Event XIX

Oct 8, 2025, 8:30 AM EDT - 4 months ago

Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement

Sep 29, 2025, 8:00 AM EDT - 5 months ago

Lisata Therapeutics Announces Encouraging Preliminary Results from the Pancreatic Cancer Cohort of the CENDIFOX Trial

Sep 2, 2025, 8:00 AM EDT - 6 months ago

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 8, 2025, 3:05 AM EDT - 7 months ago

Lisata Therapeutics, Inc. (LSTA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 7 months ago

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

Jul 17, 2025, 8:00 AM EDT - 7 months ago

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

Jul 15, 2025, 8:00 AM EDT - 8 months ago

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

Jun 17, 2025, 8:00 AM EDT - 9 months ago

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

Jun 11, 2025, 8:30 AM EDT - 9 months ago

Lisata Therapeutics to Present at the 2025 BIO International Convention

May 8, 2025, 9:57 PM EDT - 10 months ago

Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript

May 8, 2025, 4:05 PM EDT - 10 months ago

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 8:00 AM EDT - 10 months ago

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

Apr 15, 2025, 8:00 AM EDT - 11 months ago

Lisata Therapeutics Announces Research License with Catalent

Mar 6, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the Investival Showcase USA

Mar 5, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

Feb 27, 2025, 10:06 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Feb 20, 2025, 8:00 AM EST - 1 year ago

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

Jan 15, 2025, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

Dec 10, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

Nov 19, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year'

Nov 12, 2024, 10:07 PM EST - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 4:05 PM EST - 1 year ago

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 9:23 AM EST - 1 year ago

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

Nov 6, 2024, 8:30 AM EST - 1 year ago

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

Oct 31, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

Oct 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

Sep 9, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

Aug 13, 2024, 12:20 AM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

Jul 16, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma

Jul 10, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model

Jun 13, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial

May 28, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events

May 20, 2024, 8:30 AM EDT - 1 year ago

Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer

May 9, 2024, 9:42 PM EDT - 1 year ago

Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript

May 9, 2024, 4:05 PM EDT - 1 year ago

Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024, 8:00 AM EDT - 1 year ago

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

Apr 23, 2024, 7:30 AM EDT - 2 years ago

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

emile_ Feb. 23 at 6:17 PM

$LSTA why is Lisata Therapeutics falling?

0 · Reply

TwongStocks Feb. 20 at 2:19 PM

0 · Reply

BillionerOfKing Feb. 18 at 1:30 PM

$LSTA Current Stock Price: $4.56

0 · Reply

OfficialStocktwitsUser Feb. 17 at 4:00 PM

0 · Reply

InstitutionalAllocator Feb. 17 at 12:31 PM

$LSTA Pre-revenue biotech; early-stage oncology pipeline.

0 · Reply

FlowMap Feb. 9 at 2:25 PM

$LSTA Biotech or lending platform; business model is unclear from ticker.

0 · Reply

dinnerwithme Feb. 9 at 12:35 PM

$BCAB $LSTA bullish

0 · Reply

biovaluable Feb. 8 at 11:36 PM

0 · Reply

Squanchass Feb. 6 at 4:11 PM

$LSTA Give me my CVR's!

0 · Reply

biovaluable Feb. 5 at 3:22 PM

$LSTA 6

1 · Reply

BillionerOfKing Feb. 3 at 12:39 PM

$LSTA Current Stock Price: $4.57

0 · Reply

KP2021 Jan. 30 at 7:57 PM

$LSTA shorts have decreased https://www.benzinga.com/insights/short-sellers/26/01/50232004/what-does-the-market-think-about-lisata-therapeutics-inc

0 · Reply

PyraWeb Jan. 28 at 3:53 PM

$LSTA PyraWeb a breakout here STARTS at 9.63, everything else is weak defeat…see how recent candle stopped at sine wave, that tells you this is all still very controlled PA. Needs to disconnect from the algo, only way is clearing cap lvl. I’m praying Mazzo and co have finally found some creativity at the 11th hour to get this moving. We need more news! Is it their intention to sell at $4? Or was the intention to get world rights back and hope for a buyer to pop up? A few bidders maybe? I have no idea what their plan is…but this $4-5 BS isn’t it. 🙏

2 · Reply

KP2021 Jan. 28 at 1:30 PM

$LSTA

0 · Reply

KP2021 Jan. 28 at 1:26 PM

$LSTA KAVA IPO https://insights.citeline.com/scrip/business/deals/deal-watch/deal-watch-kuva-labs-to-go-public-via-merger-with-licensing-partner-lisata-TP6E7MWWG5DN7GRG6KRJTQZXTQ/

0 · Reply

KP2021 Jan. 28 at 1:19 PM

Could be another Warner Bros bid war $LSTA

0 · Reply

dinnerwithme Jan. 28 at 12:53 PM

$BCAB Additionally, $LSTA's tender offer leaves gatc with bioatla as its only partner now. What it means? GATC has top tier AI technology with a predictive accuracy of 91 percent, which is certified by UCI. The core theme of JPM2026 is the development of new AI drugs, and many companies are jumping into the market, including Nvidia thermofisher Lily. Megatrend. GATC also has a former chairman of the White House economic advisory committee. Is delisting possible?

1 · Reply

Defen Jan. 27 at 8:49 PM

$LSTA jumped early on this one

0 · Reply

ChazzyTrades Jan. 27 at 6:59 PM

$LSTA Buying here

0 · Reply

TwongStocks Jan. 27 at 3:15 PM

$LSTA This is now an arbitrage play. Per the binding term sheet, Kuva is obligated to pay: • $4 upfront • $1 CVR if the certepetide rights in China revert back to LSTA from Qilu • $1 CVR when Kuva files an NDA for any indication LSTA confirmed today that they terminated the license agreement with Qilu and that the rights in China will revert back to LSTA. So we know that one of the CVRs will pay out. Which puts the BO price at $5. LSTA is still trading ~$4.50. Market hasn't fully digested this yet. Right now the biggest risk is if this deal falls through. They have until Feb 27 to sign a definitive purchase agreement.

1 · Reply

Biotech_Pharma_Investor Jan. 27 at 3:11 PM

$LSTA Acquisition price $4.X + first CVR $1.X = $5 + potentially 2nd CVR at $1.X Yet stock trading at $4.5 still. Makes sense...

0 · Reply

MakingDreamsReality Jan. 27 at 2:25 PM

PM mOOvers👀 $HIND -Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study $NTLA -Intellia Therapeutics Announces FDA Removes Clinical Hold On Its Investigational New Drug application For MAGNITUDE-2 Phase 3 Clinical Study Of Nexiguran Ziclumeran $RR - Richtech Robotics Collaborates with Microsoft to Advance Agentic AI in Real-World Robotics Applications $ZSTK -Flora Growth Corp. Announces Name Change to ZeroStack Corp., Furthering Its Strategy as an AI-Focused Asset Management Company $LSTA -Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide

1 · Reply

Market Cap	39.52M
Revenue (ttm)	1.00M
Net Income (ttm)	-19.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,999.00%
Debt to Equity Ratio	0.00

Volume	102,700
Avg Vol	182,470
Day's Range	N/A - N/A
Shares Out	8.82M
Stochastic %K	0%
Beta	1.25
Analysts	Sell
Price Target	$9.50